GLP‑1 treatment in Vermont
Who ships GLP-1 medication to Vermont, what Medicaid covers, and the telehealth rules that apply.
What the federal data shows for Vermont
700 clinicians in Vermont prescribed Ozempic to Medicare Part D patients in 2024, across 20,117 claims. That is the most-prescribed GLP-1 in the state by prescriber count. Part D covers Medicare only, so the figure is a floor on prescribing in Vermont rather than a total.
Vermont Medicaid reimbursed $5,807,912.00 for 5,237 GLP-1 prescriptions in Q1 2026, or $1,109.02 per prescription. From CMS State Drug Utilization, fee-for-service and managed care combined. Suppressed cells are excluded, never counted as zero.
No outsourcing facility registered under section 503B gives a Vermont address in the FDA register. A compounded prescription filled for a Vermont patient is dispensed from a facility registered elsewhere.
What is on this page
- 7 drug cost pages for Vermont, each pairing the state's Medicaid figures with pharmacy acquisition cost
- Every link below is a page for Vermont specifically, not a national page filtered to it
- CMS NADACNational Average Drug Acquisition Cost, weekly file
- CMS Medicare Part DPrescriber public use file, by geography and drug
- CMS State Drug UtilizationQuarterly Medicaid prescription and reimbursement data
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.